Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent application and related technology for a gene therapy targeting both type 1 and type 2 … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported … Continue reading “Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, … Continue reading “NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast”
Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. Food and Drug Administration (“FDA”) Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor … Continue reading “Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3”
Mark Berger, M.D., Chief Medical Officer of Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing gene therapies for patients with cancer and diabetes was featured in a recent Bell2Bell Podcast episode (https://nnw.fm/oT7Wu). Dr. Berger talked about the Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of … Continue reading “Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode”
Clinical-stage gene therapy developer Genprex (NASDAQ: GNPX) is expanding the breadth of its drug candidate potential with positive results from a preclinical study that examines the anti-tumor immune response of a gene believed to play a key role in suppressing certain tumors. Genprex’s lead drug candidate, REQORSA immunogene therapy, uses Genprex’s proprietary, non-viral ONCOPREX Nanoparticle … Continue reading “Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors”
Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental … Continue reading “NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA(R) Immunogene Therapy in combination with Tagrisso(R) in late-stage non-small cell lung cancer (“NSCLC”) have been published in an abstract … Continue reading “Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer”
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System”